| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/15/2005 | US20050203050 hKIS compositions and methods of use |
| 09/15/2005 | US20050203049 Modulating the ability of a cell to affect the glycosylation state of a target selected from a lipid and a polypeptide by modulating the activity of an enzyme of either 47169 or 33935 protein; cell signaling; differentiation; tumorigenesis |
| 09/15/2005 | US20050203048 Human leucine-rich repeat containing protein expressed predominately in bone marrow, HLRRBM1 |
| 09/15/2005 | US20050203046 Modulating immune disorder or condition by administering an effective amount of an agonist or antagonist of IL-33 or IL-33 Receptor complex (IL-33R); modulates response to a number of immune and inflammatory conditions such as asthma, allergy, multiple sclerosis, inflammatory bowel disorder, arthritis |
| 09/15/2005 | US20050203045 Antisense modulation of cellular inhibitor of Apoptosis-2 expression |
| 09/15/2005 | US20050203040 siNA molecule comprising a double-stranded structure that down-regulates expression of vascular cell adhesion molecule (VCAM), wherein said siNA molecule does not require the presence of nucleotides having a 2'-hydroxy group within the siNA molecule for mediating RNA interference |
| 09/15/2005 | US20050203031 Useful for the treatment of type 2 diabetes, impaired glucose tolerance and certain other conditions |
| 09/15/2005 | US20050203030 Novel effectors of dipeptidyl peptidase IV |
| 09/15/2005 | US20050203029 Agents for treating <I>flaviviridae</I>infections |
| 09/15/2005 | US20050203027 Reduced toxicity, improved specificity for targeted protease |
| 09/15/2005 | US20050203026 Rosacea; vascular endothelial growth factor inhibitors; protease inhibitors such as Bowman-Birk Inhibitor, soybean trypsin inhibitor, and Eglin chymotrypsin inhibitor |
| 09/15/2005 | US20050203025 Compounds and methods for modulating nonclassical cadherin-mediated functions |
| 09/15/2005 | US20050203024 Peptides and methods for inducing cellular resistance to infection |
| 09/15/2005 | US20050203023 Use of rAFP inhibit or prevent apoptosis |
| 09/15/2005 | US20050203022 Type II TGF-beta receptor/immunoglobulin constant region fusion proteins |
| 09/15/2005 | US20050203021 Identifying prorenin modulators for treatment of cardiovascular and organ hypertrophy; enzyme inhibitors; mimetics; blood pressure; arterial thickening |
| 09/15/2005 | US20050203020 Safe drug administration carrier capable of extending the half life of a drug in the blood without the risk of contamination of viruses |
| 09/15/2005 | US20050203019 Pharmacoperones for correcting disease states involving protein misfolding |
| 09/15/2005 | US20050203017 For activating the non-proteolytically activated thrombin receptor |
| 09/15/2005 | US20050203015 Stable, water soluble; inhibitors of endothelial cell proliferation and of angiogenesis; tumors |
| 09/15/2005 | US20050203014 Administering agonist of hedgehog signaling; attention deficit hyperactive disorders, non-Alzheimer dementia, and various symptoms of memory loss |
| 09/15/2005 | US20050203013 Administering endostatin, thrombospondin; angiogenesis inhibitors; anticancert agents; antidiabetic agents; nephropathy; antiallergens; prevent leakage from blood vessels; vision defects; psoriasis |
| 09/15/2005 | US20050203012 Human parathyroid hormone modifications, preparation and use |
| 09/15/2005 | US20050203011 Increasing activity of glial cell line-derived neurotrophic factor (GDNF) or brain-derived neurotrophic factor (BDNF); alcohol abuse |
| 09/15/2005 | US20050203010 Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
| 09/15/2005 | US20050203009 Inhibiting VPAC1 (Vasoactive intestinal peptide)-mediated tumorigenesis; inhibits binding of pituitary adenylate cyclase-activating polypeptide (PACAP) to cell membranes |
| 09/15/2005 | US20050203008 Compositions comprising pulmonary surfactants and a polymyxin having improved surface properties |
| 09/15/2005 | US20050203007 Eglin c based drugs for treatment of disease |
| 09/15/2005 | US20050203006 Novel lipopeptides as antibacterial agents |
| 09/15/2005 | US20050203005 Peptide structure containing lanthionine and methyllanthionine as constituents isolated from Microbispora sp. ATCC PTA-5024; methicillin resistant and vancomycin resistant bacteria; M. catharralis, Neisseria species and H. influenzae and Mycobacteria |
| 09/15/2005 | US20050203003 Contulakin-G, analogs thereof and uses therefor |
| 09/15/2005 | US20050203002 Sustained release compositions for delivery of pharmaceutical proteins |
| 09/15/2005 | US20050203001 Oral insulin therapies and protocol |
| 09/15/2005 | US20050203000 Use of benzyl alcohol, and other phenolic preservatives to reduce pain during intradermal injection |
| 09/15/2005 | US20050202552 Proteins producing an altered immunogenic response and methods of making and using the same |
| 09/15/2005 | US20050202551 Proteins producing an altered immunogenic response and methods of making and using the same |
| 09/15/2005 | US20050202546 mixing an egg white or its diluted solution with diatomaceous earth, kaolin, zeolite or the mixtures thereof, followed by eluting adsorbed lysozyme with a salt solution. |
| 09/15/2005 | US20050202538 Fc-erythropoietin fusion protein with improved pharmacokinetics |
| 09/15/2005 | US20050202535 Fusion protein comprising bowman-kirk, soybean trypsin and eglin C inhibitors for use in treatment and prevention of inflammatory, arthritic and skin disorders |
| 09/15/2005 | US20050202532 Amino acid sequences for prevention and treatment of cardiovascular disease |
| 09/15/2005 | US20050202529 Humanised antibodies |
| 09/15/2005 | US20050202527 Fusion polypeptide comprising fibrinopeptide A, serine protease and thrombin-cleavable sequences for use in identifying modulators for prevention and treatment of thrombotic disorders; anticoagulants |
| 09/15/2005 | US20050202521 Using glutathione, lipid peroxide and pyroglutamic acid blood plasma concentrations as diagnostic tool for measuring a systems utilization efficiency of anti-oxidant |
| 09/15/2005 | US20050202499 Reagents and methods useful for detecting diseases of the breast |
| 09/15/2005 | US20050202498 Linkers that provide enhanced affinity and specificity to chimeric zinc finger proteins |
| 09/15/2005 | US20050202496 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 09/15/2005 | US20050202482 CD38 splice variants and uses thereof |
| 09/15/2005 | US20050202481 Novel polypeptide ESDN, polynuleotides encoding the polypeptide, and utility of the polypeptide |
| 09/15/2005 | US20050202479 Methods and materials relating to insulin growth factor-like (IGFL) polypeptides and polynucleotides |
| 09/15/2005 | US20050202478 Phosphodiesterases |
| 09/15/2005 | US20050202474 Phosphodiesterases |
| 09/15/2005 | US20050202462 Hepatic modulator for prevention and treatment of hepatic dysfunction, hepatitis and liver cancer |
| 09/15/2005 | US20050202454 "STRAP" and "STEAP"(six transmembrane (epithelial) antigen of the prostate) |
| 09/15/2005 | US20050202452 Assay determining the activity of an agent to decrease cell division; contacting protein capable of superoxide production with compound of interest and and measuring the ability of the agent to decrease superoxide production, inhibit diaphorase activity or bind the protein |
| 09/15/2005 | US20050202450 Polypeptides stable under hypoxic and nonhypoxic conditions; antihypoxic agents; myocardial necrosis and arrhythmia, strokes, autoimmune deseases, neurodegenerative disorders |
| 09/15/2005 | US20050202439 Mammalian membrane polypeptide for use in identifying modulators for prevention and treatment of urogenital disorders; contraceptives |
| 09/15/2005 | US20050202430 Nucleotide sequences coding extracellular matrix protein for use in treatment and prevention of cell proliferative disorders; promoting osteogenesis |
| 09/15/2005 | US20050202428 Notch signaling inhibitory RNA sequences for use in treatment and prevention of cell proliferative and developmental disorders |
| 09/15/2005 | US20050202424 Membrane protein for use as tool in identifying modulators for treatment of phenotype-mediated antibiotic-resistance; microbiocides; bactericides; preventing infection in cystic fibrosis patients |
| 09/15/2005 | US20050202422 Novel nucleic acids and polypeptides |
| 09/15/2005 | US20050202091 Stable pharmaceutical composition comprising erythropoietin |
| 09/15/2005 | US20050202081 Stable pharmaceutical compositions comprising ace inhibitor(s) |
| 09/15/2005 | US20050202072 Dry mouldable drug formulation |
| 09/15/2005 | US20050202071 Apparatus and methods for enzymatic escharotomy in burn induced compartment syndrome |
| 09/15/2005 | US20050202069 Polypeptide with epidermal regeneration-accelerating minimal amino acid sequences, a polyalkylenepolyamine and/or polyarylenepolyamine, and a sheet |
| 09/15/2005 | US20050202044 A fusion protein containing an antigen of an influenza virus and a bacterial stress protein; vaccines induce a cytolytic T-cell (CTL) response in a mammal |
| 09/15/2005 | US20050202042 Toxin B repeating units (rBRU) of Clostridium difficile and an antigen of a pathogenic microorganism other than C. difficile; eliciting T-cell dependent and antibody responses |
| 09/15/2005 | US20050202035 Stress protein complex; a grp170 polypeptide and an immunogenic polypeptide; antitumor |
| 09/15/2005 | US20050202033 Heat shock protein-based vaccines and immunotherapies |
| 09/15/2005 | US20050202032 Use of neglected target tissue antigens in modulation of immune responses |
| 09/15/2005 | US20050202031 Immunoglobulin specific to insect hydrolase for use in treatment and prevention of animal hyperimmune response to flea exposure; biological control agent |
| 09/15/2005 | US20050202029 Administering to reduce an immune response by modulating the trafficking of leukocytes |
| 09/15/2005 | US20050202027 Multivalent compounds for crosslinking receptors and uses thereof |
| 09/15/2005 | US20050202019 Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis |
| 09/15/2005 | US20050202017 Assay; contacting a test compound with a HB-954 polypeptide; determining whether the test compound binds to the G protein-coupled receptor |
| 09/15/2005 | US20050202016 Polypeptide; an amino acid sequence of the family of tumour-suppressing genes related to the gene for the p53 protein; isolated nucleic acid sequences coding for the proteins |
| 09/15/2005 | US20050202015 Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue |
| 09/15/2005 | US20050202014 Methods of blocking tissue destruction by autoreactive T cells |
| 09/15/2005 | US20050202013 Novel Th2-specific molecules and uses thereof |
| 09/15/2005 | US20050202011 Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith |
| 09/15/2005 | US20050202009 Novel MHC II associated peptides |
| 09/15/2005 | US20050202008 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 09/15/2005 | US20050202007 Determining a P-selectin activity in a biological sample of the subject,increased P-selectin activity in the sample indicates a procoagulant state in the subject |
| 09/15/2005 | US20050202006 EGFH2 genes and gene products |
| 09/15/2005 | US20050202004 Administering chimeric proteins, having a portion of the VH or VL region of a immunoglobulin molecule from B cells from a patient having a B cell mediated pathology; proteins conjugated to an immunogenic carrier, keyhole-limpet hemocyanin (KLH) |
| 09/15/2005 | US20050202002 Reagent; polyclonal or monoclonal antibody against the protease or its proenzyme which activates blood clotting factor VII, is inhibited by the presence of aprotinin, is increased in its activity by calcium ions, heparin, or heparin related substance |
| 09/15/2005 | US20050202001 Enhancement of human epidermal melanogenesis |
| 09/15/2005 | US20050201998 Secretin in combination with of oxytocin; irritable bowel disease, irritable bowel syndrome, diarrhea, incontinence, pelvic floor pain, biliary disorders, abdominal bloating colitis, constipation and gastrodueodenal disorders |
| 09/15/2005 | US20050201995 Neuronal cell comprising a REST-transactivator; reducing neuronal damage, neuronal loss or neurodegenerative disease |
| 09/15/2005 | US20050201985 Modified adenoviral vectors for use in vaccines and gene therapy |
| 09/15/2005 | US20050201984 An adenoviral genome replaced with a therapeutic gene or DNA sequence regulated by a ubiquitous promoter either a Cytomegalo virus promotor or a tissue-specific phosphoenolpyruvate carboxykinase promoter, where gene or sequence encodes for a latent human metalloprotease gene MMP-8 (collengenases) |
| 09/15/2005 | US20050201982 Polynucleotides encoding interferon gamma peptide variants |
| 09/15/2005 | US20050201981 Method of optimizing treatment with interferon-tau |
| 09/15/2005 | US20050201980 Method for short-term and long-term drug dosimetry |
| 09/15/2005 | US20050201979 Reduced vasopermeability activity and similar binding affinity for an IL-2 receptor compared to its wildtype form; immunostimulants; immuotherapy; anticarcinogenic agents; renal cell cancer, melanoma; chemotherapy and/or radiation therapy; viricides; human immunodeficiency virus; autoimmune disorders |
| 09/15/2005 | US20050201978 Comprising lectin coupled to an immunogeniciety modifier, pokeweed mitogen and with a coating of polyoxyethylene glycol; inhibit isoclass immunoglobulin switching; side effet reduction; antitumor, -carcinogenisis and -metastasis agents; bactericides; fungicide;antiprotazoa agents; side effect reduction |
| 09/15/2005 | US20050201977 Amino-terminally truncated MCP-2 as chemokine antagonists |
| 09/15/2005 | US20050201976 Selective inhibitors of nuclear factor-kappaB activation and uses thereof |
| 09/15/2005 | US20050201975 Modifying chemokine G-protein mediated signalling and/or signal transduction by administering a modulator of the Notch signalling pathway; using a fusion protein of a segment of a Notch ligand extracellular domain and an immunoglobulin Fc segment or a polynucleotide encoding it; antiinflammatory agents |
| 09/15/2005 | US20050201973 Therapeutic supramolecules |